Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands - PubMed (original) (raw)
Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands
K E de Visser et al. J Immunol. 2001.
Abstract
Thymic expression of self-Ags results in the deletion of high-avidity self-specific T cells, but, at least for certain Ags, a residual population of self-specific T cells with low-affinity TCRs remains after negative selection. Such self-specific T cells are thought to play a role in the induction of T cell-mediated autoimmunity, but may also be used for the induction of antitumor immunity against self-Ags. In this study, we examine the functional competence of a polyclonal population of self-specific CD8+ T cells. We show that low-affinity interactions between TCR and peptide are associated with selective loss of critical T cell functions. Triggering of low levels of IFN-gamma production and cytolytic activity through low-affinity TCRs readily occurs provided high Ag doses are used, but IL-2 production and clonal expansion are severely reduced at all Ag doses. Remarkably, a single peptide variant can form an improved ligand for the highly diverse population of low-avidity self-specific T cells and can improve their proliferative capacity. These data provide insight into the inherent limitations of self-specific T cell responses through low-avidity TCR signals and the effect of modified peptide ligands on self-specific T cell immunity.
Similar articles
- An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
Kondo K, Fujiki F, Nakajima H, Yatsukawa E, Morimoto S, Tatsumi N, Nishida S, Nakata J, Oka Y, Tsuboi A, Hosen N, Oji Y, Sugiyama H. Kondo K, et al. J Immunother. 2016 Apr;39(3):127-39. doi: 10.1097/CJI.0000000000000114. J Immunother. 2016. PMID: 26938946 - T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity.
Sandberg JK, Franksson L, Sundbäck J, Michaelsson J, Petersson M, Achour A, Wallin RP, Sherman NE, Bergman T, Jörnvall H, Hunt DF, Kiessling R, Kärre K. Sandberg JK, et al. J Immunol. 2000 Jul 1;165(1):25-33. doi: 10.4049/jimmunol.165.1.25. J Immunol. 2000. PMID: 10861031 - Affinity of thymic self-peptides for the TCR determines the selection of CD8(+) T lymphocytes in the thymus.
Ober BT, Hu Q, Opferman JT, Hagevik S, Chiu N, Wang CR, Ashton-Rickardt PG. Ober BT, et al. Int Immunol. 2000 Sep;12(9):1353-63. doi: 10.1093/intimm/12.9.1353. Int Immunol. 2000. PMID: 10967031 - Role of TCR specificity in CD4+ CD25+ regulatory T-cell selection.
Picca CC, Larkin J 3rd, Boesteanu A, Lerman MA, Rankin AL, Caton AJ. Picca CC, et al. Immunol Rev. 2006 Aug;212:74-85. doi: 10.1111/j.0105-2896.2006.00416.x. Immunol Rev. 2006. PMID: 16903907 Review. - Structural alterations in peptide-MHC recognition by self-reactive T cell receptors.
Wucherpfennig KW, Call MJ, Deng L, Mariuzza R. Wucherpfennig KW, et al. Curr Opin Immunol. 2009 Dec;21(6):590-5. doi: 10.1016/j.coi.2009.07.008. Epub 2009 Aug 19. Curr Opin Immunol. 2009. PMID: 19699075 Free PMC article. Review.
Cited by
- Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma.
Grace BE, Backlund CM, Morgan DM, Kang BH, Singh NK, Huisman BD, Rappazzo CG, Moynihan KD, Maiorino L, Dobson CS, Kyung T, Gordon KS, Holec PV, Mbah OCT, Garafola D, Wu S, Love JC, Wittrup KD, Irvine DJ, Birnbaum ME. Grace BE, et al. Front Immunol. 2022 Jun 23;13:886683. doi: 10.3389/fimmu.2022.886683. eCollection 2022. Front Immunol. 2022. PMID: 35812387 Free PMC article. - An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity.
He X, Zhou S, Quinn B, Jahagirdar D, Ortega J, Long MD, Abrams SI, Lovell JF. He X, et al. Cancer Immunol Res. 2022 Mar 1;10(3):314-326. doi: 10.1158/2326-6066.CIR-21-0332. Cancer Immunol Res. 2022. PMID: 34992135 Free PMC article. - Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density.
Gilfillan CB, Wang C, Mohsen MO, Rufer N, Hebeisen M, Allard M, Verdeil G, Irvine DJ, Bachmann MF, Speiser DE. Gilfillan CB, et al. Eur J Immunol. 2020 Apr;50(4):505-514. doi: 10.1002/eji.201948355. Epub 2019 Dec 10. Eur J Immunol. 2020. PMID: 31785153 Free PMC article. - Peptide vaccines for hematological malignancies: a missed promise?
Bocchia M, Defina M, Aprile L, Sicuranza A. Bocchia M, et al. Int J Hematol. 2014 Feb;99(2):107-16. doi: 10.1007/s12185-013-1497-3. Epub 2014 Jan 8. Int J Hematol. 2014. PMID: 24399190 Review. - Improving antigenic peptide vaccines for cancer immunotherapy using a dominant tumor-specific T cell receptor.
Buhrman JD, Jordan KR, Munson DJ, Moore BL, Kappler JW, Slansky JE. Buhrman JD, et al. J Biol Chem. 2013 Nov 15;288(46):33213-25. doi: 10.1074/jbc.M113.509554. Epub 2013 Oct 8. J Biol Chem. 2013. PMID: 24106273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials